Jazz Pharmaceuticals is committed to supporting programs open to a broad audience that benefit patients and the scientific or medical community, and/or public health; these support requests are healthcare-related and consistent with a therapeutic area of focus or interest at Jazz Pharmaceuticals, including the areas of sleep and hematology/oncology.
Funding priorities include:
- Advocacy community and patient education on disease, diagnosis, care and access
- Patient support services and resources
- Patient outreach initiatives
- Fundraising events and activities
- Health screenings
Eligible organizations must be non-profit patient organizations that support awareness, study or treatment of diseases in Jazz Pharmaceuticals’ therapeutic areas of focus (sleep and hematology/oncology); support the improvement of communities in which our employees live and work; or otherwise support the corporate strategy and interests of Jazz Pharmaceuticals.
Please note that in order to be eligible for a charitable contribution, any U.S. applicant must be a tax-exempt organization under Section 501(c)-(3) or 501(c)-(6) of the U.S. Internal Revenue Code.
Jazz Pharmaceuticals generally does not provide corporate giving for: Individuals, individual scholarships and individual travel support; government agencies, employees and contractors; general education funds (e.g., must be a specific program or event); political purposes; religious purposes; initiatives that pose a conflict of interest with the commercial or development goals of Jazz Pharmaceuticals; or retrospective or aggregated grants.
Across all of our giving, funding must be consistent with Jazz Pharmaceuticals’ compliance policies and corporate objectives, and such funding cannot violate any applicable FDA or federal health care program requirements. The use, purchase or prescription of Jazz Pharmaceuticals’ products or the recipient’s potential to influence the use, purchase or prescription of those products are independent from corporate giving and may not be considered when deciding on a corporate contribution request.